Robert Driscoll's questions to Compass Therapeutics Inc. (CMPX) leadership • Q2 2025
Question
Robert Driscoll of Wedbush Securities questioned whether the CTX-8371 expansion cohorts would select for PD-L1 expression and asked about the profile of immune-related adverse events (irAEs) observed so far.
Answer
CEO Thomas Schuetz stated that the expansion cohorts will not select for PD-L1 expression, maintaining the same criteria as the dose-escalation phase. Regarding safety, he noted no dose-limiting toxicities were seen in the first four cohorts and speculated that the drug's mechanism could potentially lead to a better safety profile, though more data is needed.